Search

Your search keyword '"Nout, Remi A"' showing total 846 results

Search Constraints

Start Over You searched for: Author "Nout, Remi A" Remove constraint Author: "Nout, Remi A"
846 results on '"Nout, Remi A"'

Search Results

201. Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis

202. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study

205. Correction to: Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer

207. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients - a TransPORTEC study

208. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

210. Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis

211. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis

212. Response to Yuce Sari et al.

213. An anthropomorphic deformable phantom of the vaginal wall and cavity

214. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin:a systematic review

215. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

216. Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial

217. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System:Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System

218. Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer

219. Adjuvant systemic therapy after chemoradiation and brachytherapy for locally advanced cervical cancer:A systematic review and meta-analysis

220. Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors

221. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva:An efficacy study

222. An anthropomorphic deformable phantom of the vaginal wall and cavity

224. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis

225. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

226. Response to Yuce Sari et al.

227. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

228. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network

229. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study

232. Postgraduate education in radiation oncology during the COVID-19 pandemic – What did we learn?

235. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis

236. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

237. Image-Guided Adaptive Brachytherapy (IGABT) for Primary Vaginal Cancer: Results of the International Multicenter RetroEMBRAVE Cohort Study

238. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

239. Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study

240. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial

241. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network

243. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

244. In Reply to Murakami et al.

245. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy

246. Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study

247. PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

248. Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study

249. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

250. Phantom-based quality assurance for multicenter quantitative MRI in locally advanced cervical cancer

Catalog

Books, media, physical & digital resources